Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
90.06 EUR | +2.39% |
|
+0.66% | -1.71% |
06-27 | CAC40: caution prevails ahead of crucial deadlines | CF |
06-27 | CAC40: consolidates solo, OAT/Bund spread widens to 81Pb | CF |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
Strengths
- Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
- The group's high margin levels account for strong profits.
- The company is in a robust financial situation considering its net cash and margin position.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- The opinion of analysts covering the stock has improved over the past four months.
- Over the past twelve months, analysts' opinions have been strongly revised upwards.
Weaknesses
- For the past year, analysts have significantly revised downwards their profit estimates.
Ratings chart - Surperformance
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-1.71% | 120B | - | ||
+55.95% | 819B | C+ | ||
+43.62% | 638B | B | ||
-6.98% | 351B | C+ | ||
+19.08% | 329B | B- | ||
+9.05% | 298B | C+ | ||
+16.82% | 242B | B+ | ||
+2.54% | 225B | A+ | ||
+13.06% | 217B | B- | ||
+8.91% | 168B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- SAN Stock
- SANO Stock
- Ratings Sanofi